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Berberine, a natural lipid-lowering drug, exerts prothrombotic
effects on vascular cells
Abstract
Berberine (BBR) is a novel natural hypolipidemic agent. This study investigates whether BBR, similar
to statins, exerts pleiotropic effects on endothelial tissue factor (TF) expression. BBR enhanced tumor
necrosis factor-alpha (TNF-alpha) and thrombin induced TF expression in human endothelial cells by
3.5-fold. These effects were paralleled by an enhanced TF surface activity. In contrast, expression of TF
pathway inhibitor was impaired. BBR enhanced TNF-alpha induced TF mRNA expression; however,
TF promoter activity was inhibited. Activation of ERK and p38 remained unaffected, while c-Jun
terminal NH(2) kinase was inhibited. BBR reduced TF mRNA degradation rates, prolonging its half-life
from 1.1 to 4.3 h. The HMG-CoA reductase inhibitor simvastatin impaired thrombin induced TF
expression, and BBR blunted this inhibition. Simvastatin did not affect TNF-alpha induced TF
expression, and BBR enhanced TF under these conditions. Administration of BBR (100 mg/kg/d)
increased TF activity and impaired TFPI expression in carotid artery of ApoE(-/-) mice. BBR enhances
TF via mRNA stabilization at clinically relevant concentrations. Clinical application of BBR, either as
an alternative to or in combination with statins, should be considered with caution.
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Abstract 
 
Aims. Berberine (BBR) is a novel natural hypolipidemic agent. This study 
investigates whether BBR, similar to statins, exerts pleiotropic effects on 
endothelial tissue factor (TF) expression.  
Methods and Results. BBR enhanced tumor necrosis factor-α (TNF-α) and 
thrombin induced TF expression in human endothelial cells by 3.5-fold. These 
effects were paralleled by an enhanced TF surface activity. In contrast, 
expression of TF pathway inhibitor was impaired. BBR enhanced TNF-α 
induced TF mRNA expression; however, TF promoter activity was inhibited.  
Activation ERK and p38 remained unaffected, while c-Jun terminal NH2 kinase 
was inhibited. BBR reduced TF mRNA degradation rates, prolonging its half-life 
from 1.1 to 4.3 hours. The HMG-CoA reductase inhibitor simvastatin impaired 
thrombin induced TF expression, and BBR blunted this inhibition. Simvastatin 
did not affect TNF-α induced TF expression, and BBR enhanced TF under 
these conditions. Administration of BBR (100 mg/kg/d) increased TF activity and 
impaired TFPI expression in carotid artery of ApoE-/- mice. 
Conclusions. BBR enhances TF via mRNA stabilization at clinically relevant 
concentrations. Clinical application of BBR, either as an alternative to or in 
combination with statins, should be considered with caution. 
 
Key Words: Berberine, Tissue Factor, Tissue Factor Pathway Inhibitor, mRNA 
Stability, Simvastatin 
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Introduction 
 
Arterial thrombosis is the critical event in acute coronary syndromes, 
peripheral ischemia, and stroke. Tissue factor (TF) plays an essential role in 
coagulation by binding factor VII, which activates factor X, finally leading to 
thrombin generation [1]. TF expression is detected in a variety of cell types 
within the atherosclerotic vessel wall and is induced by inflammatory mediators 
such as TNF-α, histamine, or lipopolysaccharide [2,3,4,5]. Elevated levels of TF 
are indeed present in plaques from patients with unstable angina and enhance 
plaque thrombogenicity; further, an involvement of TF in drug-eluting stent 
thrombosis has been discussed as well [6,7,8]. Tissue factor pathway inhibitor 
(TFPI) acts as the direct endogenous inhibitor of the TF/FVIIa complex [9]. 
Increasing evidence indicates that modulation of the physiological balance 
between TF and TFPI has an important impact on thrombus formation [10,11]. 
Berberine (BBR), an alkaloid isolated from the chinese herb huanglian 
(Coptis chinensis), has been extensively used in traditional Chinese medicine. 
Recently, BBR was identified as a promising lipid-lowering drug, potently 
upregulating hepatic low-density lipoprotein (LDL) receptor expression. This 
effect occurred via LDL receptor mRNA stabilization rather than increased 
promoter activity and required extracellular signal regulated kinase (ERK) 
activation [12]. Further studies revealed that the BBR induced LDL receptor 
mRNA stabilization involved novel regulatory proteins located downstream of 
the ERK pathway and able to interact with sequences in the proximal section of 
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the LDL receptor mRNA 3’ untranslated region (UTR) [13]. 
Since these observations suggest a therapeutic application of BBR, 
either as a monotherapy or in combination with statins, this study adressed the 
question whether BBR, similar to statins, exerts pleiotropic effects on 
endothelial TF expression. 
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Methods 
 
Cell Culture 
Human aortic endothelial cells (HAEC; Clonetics, Allschwil, Switzerland) 
were cultured as described [3,4]. Adhering cells were grown to confluence in 3 
cm dishes and rendered quiescent in medium supplemented with 0,5% fetal 
bovine serum for 24 hours before stimulation with 5 ng/mL TNF-α (R&D 
Systems, Minneapolis, MN) or 1 U/ml thrombin (Sigma, St. Louis, MO). Cells 
were treated with BBR (Cayman Chemical, Ann Arbor, MI), simvastatin (Sigma), 
or both for 60 min prior to stimulation. Cytotoxicity was assessed with a 
colorimetric assay for detection of lactate dehydrogenase release (Roche, 
Basel, Switzerland). 
 
Western Blot 
Protein expression was determined by Western blot analysis as 
described [3,4]. Antibodies against human TF and TFPI (both from American 
Diagnostica, Stamford, CT) were used at 1:2000 dilution. Antibodies against  
phosphorylated p38 MAP kinase (p38), p44/42 MAP kinase (extracellular signal 
regulated kinase [ERK]), and c-Jun NH2-terminal kinase (JNK; all from Cell 
Signaling, Danvers, MA) were used at 1:1000, 1:5000, and 1:1000 dilution, 
respectively. Antibodies against total p38, ERK, and JNK (all from Cell 
Signaling) were used at 1:2000, 1:5000, and 1:1000 dilution, respectively. All 
blots were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
expression (1:5000 dilution, Chemicon International, Temecula, CA).  
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TF Surface Activity 
TF activity at the surface of HAEC was analyzed using a colorimetric 
assay (American Diagnostica) [3,4]. TF/FVIIa complex converted human factor 
X to factor Xa, which was measured by its ability to metabolize a chromogenic 
substrate. TF activity was measured against a standard curve performed with 
lipidated human TF to assure that measurements were taken in the linear range 
of detection. 
 
Real Time PCR 
Total RNA was extracted from HAEC using TRIzol Reagent (Invitrogen, 
Carlsbad, CA). Conversion of total cellular RNA to cDNA was carried out with 
Moloney murine leukemia virus reverse transcriptase and random hexamer 
primers (Amersham Biosciences, Piscataway, NJ) in a final volume of 33 µl 
using 4 µg of cDNA. Real time PCR was performed in an MX3000P PCR cycler 
(Stratagene, Amsterdam, The Netherlands) as described [7,8]. All experiments 
were performed using the SYBR Green JumpStart kit (Sigma). Each reaction 
(25 µl) contained 2 µl cDNA, 1 pmol of each primer, 0.25 µl of internal reference 
dye, and 12.5 µl of JumpStart Taq ReadyMix (containing buffer, dNTPs, 
stabilizers, SYBR Green, Taq polymerase and JumpStart Taq antibody). The 
following primers were used: for full length human TF (F3): sense 5’-TCCCCA-
GAGTTCACACCTTACC–3’, antisense 5’–CCTTTCTCCTGGCCCATACAC–3’ 
(bases 843-863 of F3 cDNA; NCBI no. NM 001993); for human ribosomal L28: 
sense 5’-GCATCTGCAATGGATGGT-3’, antisense 5’–
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CCTTTCTCCTGGCCCATACAC-3’. The amplification program consisted of 1 
cycle at 95˚C for 10 min, followed by 35 cycles with a denaturing phase at 95˚C 
for 30 s, an annealing phase at 60˚C for 1 min, and an elongation phase at 72˚C 
for 1 min. A melting curve analysis was performed after amplification to verify 
the accuracy of the amplicon, and PCR products were analyzed on an ethidium 
bromide stained 1% agarose gel. In each real-time PCR run for TF and L28, a 
calibration curve was included that was generated from serial dilutions of 
purified amplicons.  
 
TF Promoter Activity 
The TF promoter (-227 bp to +121 bp) was inserted upstream of the 
luciferase cDNA and the SV40 PolyA signal into the multiple cloning site of the 
helper vector VQAd5K-NpA (provided by ViraQuest Inc., North Liberty, IA). In a 
first step, HindIII and BamHI restriction sites of VQAd5K-NpA were used to 
insert a 2.7 kb HindIII/BamHI restriction fragment of pGL2-Basic vector 
(Promega, Madison, WI) containing the luciferase cDNA and the SV40 PolyA 
signal. In a second step, a 0.3 kb Kpnl restriction fragment from a human TF 
promoter plasmid including the TF minimal promoter [14] kindly provided by Dr. 
Nigel Mackman (University of North Carolina, Chapell Hill; NC) was ligated into 
the Kpnl site of the resulting construct. The whole insert was sequenced to 
confirm its orientation and the absence of any nucleotide substitutions. This 
construct named VQAd5/hTF/Luc was used for production of an adenoviral 
vector (Ad5/hTF/Luc). For transduction, the vector was added to HAEC at an 
moi of 60 pfu/cell for 1 hour and then removed. HAEC were kept in growth 
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medium for 24 hours and then serum-starved for 24 hours prior to TNF-α 
stimulation with or without BBR (30 µmol/L) for 5 hours. Firefly luciferase activity 
was determined in cell lysates using a luminometer (Berthold Technologies, 
Bad Wildbad, Germany). Protein concentration of the cell lysates was 
determined for normalization of luciferase activity. 
 
TF mRNA Stability 
2 hours after TNF-α stimulation, transcription was stopped by addition of 
actinomycin D (Sigma, St. Louis, MO) at a concentration of 10 µg/ml. At the 
indicated time points following addition of actinomycin D, cells were washed 
with PBS and immediately lysed with TRIzol reagent for RNA isolation. RNA 
was processed for real-time PCR analysis as described above. Values were 
then plotted on a logarithmic scale as a function of time, and the half-life was 
calculated using linear equation [15]. 
 
In vitro RNA decay assay 
A 297-bp PCR fragment from 3‘-UTR of the human TF cDNA was subcloned 
into the BamHI and XhoI restriction sites of pBluescript II KS (+) (Stratagene). 
This construct was linearized with KpnI and used as a template for generation 
of a 390-nt riboprobe labeled with 50 µCi [α-32P]UTP (25 Ci/mmol, Perkin 
Elmer) using T7 RNA polymerase (Promega) and m7G5’pppG (cap). The 
labeling reaction was performed for 1 h at 30°C fol lowed by removal of the DNA 
template through incubation with RQ1 RNase-Free DNase for 15 min at 37°C. 
The riboprobe was then purified on 6% Tris boric acid-EDTA buffer-urea 
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polyacrylamide gel. Cytoplasmic proteins were extracted in lysis buffer (25 mM 
HEPES, pH 7.6, 5 mM MgCl2, 1.5 mM KCl, 2 mM DTT, 1 mM PMSF, 0.1% NP-
40). 32P-labeled riboprobe (105 cpm) was added to 20 µg cytoplasmic protein 
extracts (1 µg protein/µl) in buffer (20 mM HEPES (pH 7.0), 20% glycerol, 100 
mM KCl, 0.2 mM EDTA, 1 mM DTT, 1mM PMSF), and this mixture incubated at 
room temperature in RNA-binding buffer (20 µl) containing 20 mM HEPES (pH 
7.0), 20% glycerol, 100 mM KCl, 3 mM MgCl2, 2 mM DTT, 0.5 % NP-40, yeast 
RNA (1 µg), and heparin (1 µg). Aliquots were removed at 0 min, 15 min, 30 
min, and 60 min time-points and placed in 100 µl stop solution containing 25 
mM Tris (pH 7.6), 400 mM NaCl, 0.1 % SDS, and yeast RNA (10 µg). Samples 
were extracted with phenol-cloroform, precipitated with ethanol, and separated 
by gel-electrophoresis on 5% polyacrylamide gel containing 7M urea. Bands 
were visualized by autoradiography using a phosphoimager. 
 
In vivo study 
For analysis of TF and TFPI in vivo, 10 week old male ApoE-/- mice (C57BL6, 
Jackson Laboratories, Bar Harbor, ME) weighing an average of 28g were fed a 
normal chow diet (KLIBA NAFAG, Kaiseraugst, Switzerland) and treated with 
BBR at a dose of 100 mg/kg/d orally for 10 days. Control ApoE-/- mice matched 
for age, sex, and weight received an equal volume of vehicle (0.9% saline). 
Mice were then euthanized and the left common carotid artery harvested for 
analysis of TF activity and TFPI expression. Analysis of TF activity in the arterial 
homogenates was performed using a colorimetric assay (American 
Diagnostica). TFPI expression was assessed by ELISA (American Diagnostica). 
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Statistics 
Data are presented as mean±SEM. Statistical analysis was performed by 
ANOVA or 2-tailed unpaired Student t-test as appropriate. A value of p<0.05 
was considered significant. All results are representative of at least 4 
independent experiments. 
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Results 
 
Berberine enhances TF protein expression and surface activity 
HAEC were stimulated with TNF-α (5 ng/ml) or thrombin (1 U/ml) for 5 
hours. 1 hour pretreatment with BBR (1-30 µmol/l) enhanced TNF-α induced TF 
expression in a concentration-dependent manner with an EC50 value of 2 
µmol/l (n=5; p<0.01; Figure 1A); the maximal effect occurred at 30 µmol/l and 
resulted in a 3.4-fold higher expression as compared to TNF-α alone. Similarly, 
BBR enhanced thrombin induced TF expression by 3.3-fold as compared to 
thrombin alone (n=5; p<0.05; Figure 1B). BBR did not alter TF expression under 
basal conditions (n=10; p=NS; Figure 1A and B). The effect of BBR on TF 
expression was paralleled by an enhanced TF surface activity, which was 1.6 
times higher than that by TNF-α alone (n=4; p<0.0005; Figure 1C). BBR did not 
alter TF surface activity under basal conditions (n=4; p=NS; Figure 1C).  
BBR (1-30 µmol/l) inhibited TFPI expression of TNF-α stimulated HAEC 
by 45±15% as compared to TNF-α alone with an EC50 value of 5.7 µmol/l (n=4; 
p<0.05; Figure 1D). Similarly, BBR impaired basal TFPI expression by 52±12% 
(n=4; p<0.005; Figure 1D). 
LDH release was not affected by any BBR concentration used (n=4; 
p=NS; data not shown) indicating that BBR did not exert cytotoxic effects.  
 
Berberine enhances TF mRNA level  
Real-time PCR revealed that TNF-α induced TF mRNA expression within 
2 hours of stimulation (n=5; p<0.0001; Figure 2A). BBR (30 µmol/l) enhanced 
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TNF-α induced TF mRNA expression by 1.6-fold as compared to TNF-α alone 
(n=5; p<0.05; Figure 2A).  
 
Berberine inhibits TF promoter activity  
To assess whether the effect on TF mRNA was mediated by enhanced 
transcription, the impact of BBR on TF promoter activity was analyzed after 
transfection of HAEC with a plasmid expressing firefly luciferase under control 
of the human TF promoter (-221bp to +121bp). TNF-α enhanced TF promoter 
activity by 2.9-fold as compared to control conditions (n=4; p<0.0001; Figure 
2B). Treatment with BBR (30 µmol/l) impaired promoter activation (n=4; 
p<0.001; Figure 2B). BBR did not affect basal promoter activity (n=4; p=NS; 
Figure 2B). 
 
Berberine inhibits JNK phosphorylation 
To determine whether inhibition of TF promoter activity was paralleled by 
inhibition of MAP kinases, phosphorylation of these mediators was assessed at 
different time points after TNF-α stimulation. TNF-α (5 ng/mL) transiently 
activated JNK, ERK, and p38; maximal activation was observed after 15 
minutes and returned to basal levels within 60 minutes (Figure 3A). Treatment 
with BBR inhibited phosphorylation of JNK by 48±12% as compared to TNF-α 
alone (n=4; p<0.05; Figure 3B), while phosphorylation of ERK and p38 was not 
significantly reduced (n=4; p=NS; Figure 3B). Total expression of JNK, ERK, 
and p38 remained unaffected at all time points examined (Figure 3A). 
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Berberine stabilizes TF mRNA  
TF mRNA was quantified by real-time PCR at different time points after 
addition of the inhibitor of transcription, actinomycin D. BBR (30 µmol/L) 
delayed TF mRNA degradation, increasing the half-life of TF mRNA from 64 
min under control conditions to 260 min in the presence of BBR (n=5; Figure 
4A). To study the role of the 3'-untranslated region (3’-UTR), which includes five 
AU-rich elements known to mediate TF mRNA stability, an in vitro RNA decay 
assay was performed. A 32P-radiolabeled 390 nt transcript containing the last 
297 nt of the TF 3’-UTR was incubated with cytoplasmatic extracts generated 
from endothelial cells either untreated or treated with TNF-α, berberine, or TNF-
α+berberine. Analysis of transcript decay by densitometry showed no significant 
difference in transcript degradation rate between the different groups (n=4; 
p=NS; Figure 4B). 
 
Berberine abrogates the inhibitory action of statins on TF expression  
Statins exert pleiotropic anti-thrombotic effects through inhibition of TF 
expression in different cell types including endothelial cells [16,17,18].  Since 
statins and BBR exhibit additive lipid-lowering effects, the impact of such a 
combination on endothelial TF protein expression was examined. Simvastatin (1 
µmol/l) inhibited thrombin induced TF expression by 40±14% as compared to 
thrombin alone (n=5; p<0.05; Figure 5A), while such an effect was not observed 
in TNF-α stimulated endothelial cells (n=4; p=NS for TNF-α + simvastatin vs 
TNF-α alone; Figure 5B). BBR antagonized the inhibitory effect of simvastatin 
on thrombin induced TF expression (n=5; p<0.05 for simvastatin + BBR vs 
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simvastatin alone; p=NS for simvastatin + BBR vs BBR alone; Figure 5A). In 
both thrombin and TNF-α stimulated HAEC, treatment with simvastatin had no 
effect on the enhanced TF expression occurring in the presence of BBR (n=4; 
p=NS; Figure 5B).  
 
BBR enhances TF and inhibits TFPI in vivo 
The effect of berberine on expression of TF and TFPI was assessed in 
ApoE-/- mice. Animals were treated for 10 days with berberine (100 mg/kg/d). 
The left common carotid artery was harvested for analysis of TF activity and 
TFPI expression. TF activity was enhanced by nearly 2-fold in the berberine 
treated group (n=7; p<0.05; Figure 6A). This increase in TF activity was 
paralleled by a 43.5% decrease in TFPI expression as compared to control 
(n=7; p<0.05; Figure 6B). 
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Discussion 
 
This study demonstrates that BBR, at clinically relevant concentrations 
stimulating hepatic LDL receptor expression [12], enhances TNF-α and 
thrombin induced endothelial TF expression via stabilization of TF mRNA. 
Moreover, BBR inhibits endothelial TFPI expression, and abrogates the 
inhibitory effects of statins on endothelial TF. Similar effects on TF and TFPI are 
observed in ApoE-/- mice treated with BBR. These observations suggest that 
application of BBR as a lipid-lowering medication, either alone or in combination 
with a statin, may favor the development of thrombosis, in particular in the 
inflammatory environment of atherosclerotic lesions [19]. 
As endothelial cells are situated at the luminal surface of vessels and 
thereby exposed to circulating FVII, modulation of TF expression at the 
endothelial surface can have major consequences for thrombus formation. BBR 
enhanced TNF-α and thrombin induced TF expression, suggesting that it 
promotes thrombus formation under both inflammatory and prothrombotic 
conditions. Since TF is inhibited by TFPI, the balance of these factors is 
essential for vascular homeostasis [9,10,20]. In addition to enhancing TF, BBR 
impaired basal as well as TNF-α induced endothelial TFPI expression, which 
represents an additional prothrombotic potential. These effects of BBR on TF 
and TFPI may be particularly relevant in acute coronary syndromes, which are 
usually triggered by vascular inflammation leading to thrombus formation. 
The BBR concentrations applied in vitro (1 to 30 µmol/l) are comparable 
to those used in another study [12], where concentrations ranged from 0.5 to 15 
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µg/ml corresponding to 1.3 to 40 µmol/l. The pharmacokinetics of berberine in 
humans are barely understood and still need to be characterized. However, a 
study performed in patients with congestive heart failure reported that oral 
administration of 1.2 g BBR per day led to plasma concentrations of 190±0.08 
ng/ml (0.5±0.03 µmol/l) [21]. For the in vivo animal studies performed by others 
as well as for our own in vivo experiments, BBR was administrated orally at a 
dose of 50 and 100 mg/kg/d corresponding to an oral intake of 3 and 6 g BBR 
per day, respectively, for an adult weighing 60 kg [12]; hence, BBR intake was 
higher than in the study performed in humans, suggesting that BBR plasma 
concentrations may well reach values of 2 µmol/l under these conditions. The 
berberine mediated effects on endothelial TF were statistically significant at 
concentrations as low as 1 µmol/l, and consistent with a biologically relevant 
concentration range, the in vivo effects of BBR on TF and TFPI were similar to 
those observed in human cells. 
The MAP kinases JNK, ERK, and p38 are critically involved in mediating 
transcriptional regulation of TF expression in response to both TNF-α and 
thrombin [1]. Although BBR enhanced TF mRNA levels, it inhibited activation of 
JNK without affecting that of ERK and p38, and, in line with this observation, 
impaired TF promoter activation. These data indicate that BBR upregulates TF 
mRNA by a post-transcriptional mechanism able to counteract the impaired TF 
promoter activation. Analysis of TF mRNA decay rates indeed confirmed that 
BBR prolonged the half life of TF mRNA from 64 to 260 minutes, highlighting 
the crucial role of mRNA stability in the regulation of TF expression. A similar 
effect on the half life of TF mRNA was observed with dexamethasone in human 
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monocytes [5,22]. The importance of mRNA stability in mediating TF 
expression, however, varies depending on the stimulus involved; indeed, LPS 
induces TF mainly by enhancing mRNA stability rather than increasing the rate 
of transcription, while the opposite effect accounts for the action of PMA [23]. 
Hence, it is conceivable that the mechanism of action of BBR on endothelial TF 
expression differs depending on the stimulus activating the endothelium. 
In mammalian cells, AU sequences regrouped to AUUUA pentamers in 
so-called AU-rich elements (ARE) located in the 3’ untranslated region of mRNA 
are known to modulate mRNA decay [12,24,25]. ARE have been described in 
the 3’-UTR of human TF mRNA and are involved in TF mRNA turnover [22,26]. 
Analysis of the decay rates of a 390 nt transcript containing the last 297 nt of 
the TF 3’-UTR suggested that the stabilizing effect of berberine on TF mRNA is 
not mediated by elements within the last 297 nt of the TF 3’-UTR since there 
was no difference in degradation rates of the transcript in the presence of 
cytoplasmatic extracts from cells treated with or without BBR. 3’-UTR ARE and 
their binding proteins are not the only regulators of mRNA stability; other 
mechanisms such as inhibition of translational elongation or the presence of 
stabilizing sequences located in the 5’-UTR can modulate mRNA decay as well 
[23,24]. So far, however, it remains unknown whether the latter mechanisms are 
involved in regulating TF mRNA stability. 
Statins are among the most-widely prescribed drugs, and the indications 
for their prescription have been extended over the years. Besides their well 
established lipid-lowering properties, statins exert cardio-protective pleiotropic 
effects [27,28]. Simvastatin indeed inhibited thrombin induced endothelial TF 
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expression; however, TNF-α induced TF expression was not affected, indicating 
that such pleiotropic effects are modulated by the mediators involved in 
endothelial activation. Since another statin, cerivastatin, prevented TNF-α 
induced TF expression in human endothelial cells [29], this class of drugs may 
be heterogenous with regard to modulation of TF expression; alternatively, it 
should be considered that this experiment was performed in human umbilical 
vein endothelial cells and that experimental conditions might vary. BBR blunted 
the inhibitory effect of simvastatin on thrombin induced TF expression; 
moreover, it enhanced TF expression in cells treated with either TNF-α alone or 
TNF-α together with simvastatin. Both effects can be explained by the 
posttranscriptional mechanisms through which BBR enhances TF expression. 
 In summary, this study reveals that the natural lipid-lowering drug, BBR, 
enhances TF expression and in parallel decreases TFPI expression both in 
human endothelial cells and in arteries of ApoE-/- mice. Hence, BBR may favor 
the development of thrombus formation, particularly in patients with 
atherosclerotic lesions and those with acute coronary syndromes, since 
prothrombotic and inflammatory environments are often encountered under 
these conditions. Therefore, clinical application of BBR should be considered 
with caution, at least until large-scale clinical trials have proven its safety. 
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Figure Legends 
 
Figure 1: BBR enhances TF protein expression and surface activity, and 
inhibits TFPI expression  
Western blot analysis demonstrates that BBR enhances TNF-α (A) and 
thrombin (B) induced TF protein expression. *p<0.01 vs TNF-α alone, *p<0.05 
vs thrombin alone. C. BBR enhances TNF-α induced TF surface activity. 
*p<0.001 vs TNF-α alone. D. BBR inhibits TFPI protein expression. *p<0.005 vs 
control; **p<0.05 vs. TNF-α alone. All blots are normalized to GAPDH  
expression. 
 
Figure 2: BBR enhances TF mRNA expression, but inhibits TF promoter  
activation. 
A. Real-time PCR demonstrates that BBR enhances TNF-α induced TF 
mRNA expression. Values are normalized to L28 expression. *p<0.005 vs TNF-
α alone. B. BBR inhibits TNF-α induced TF promoter activation. Values are 
normalized to total protein concentration. *p<0.001 vs TNF-α alone.  
 
Figure 3: BBR inhibits JNK phosphorylation. 
A. TNF-α leads to transient phosphorylation (Pho) of JNK, ERK, and p38. 
BBR inhibits activation of JNK, but not ERK and p38. Total (tot) expression of 
JNK, ERK, and p38 remains unchanged. B. BBR inhibits phosphorylation of 
JNK after 15 minutes of TNF-α stimulation. *p<0.05 vs TNF-α alone. 
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Figure 4: BBR stabilizes TF mRNA 
A. The decay of TF mRNA after addition of actinomycin D is monitored 
by real time PCR and normalized to L28 mRNA. Normalized TF mRNA levels 
are plotted in a semi-logarithmic scale as percentage of mRNA remaining 
versus time. The half-lives of TF mRNA are indicated. B. In vitro RNA decay 
assay reveals that the 3’UTR is not involved in the effect of BBR on TF mRNA. 
p=NS vs control. 
 
Figure 5: BBR abrogates TF inhibition by simvastatin 
A. Simvastatin inhibits thrombin induced TF expression as determined by 
western blot.**p<0.05 vs thrombin alone. BBR abrogates this effect. *p<0.05 vs 
thrombin alone, *p<0.05 vs thrombin + simvastatin. B. Simvastatin does not 
affect TNF-α induced TF expression. p=NS vs TNF-α alone. BBR enhances TF 
expression in the presence of simvastatin. *p<0.05 vs TNF-α alone, *p<0.05 vs 
TNF-α + simvastatin. 
 
Figure 6: BBR enhances TF and inhibits TFPI in vivo 
A. BBR enhances TF activity in ApoE-/- mice. *p<0.05 vs control. B. BBR 
inhibits TFPI expression in ApoE-/- mice. *p<0.05 vs control. 
